Biotalk

Biotalk

Locust Walk

Vizitează neapărat site-ul podcastului și susține-i creatorul: www.locustwalk.com

Autor

Biotalk

Categorie

Education

Site-ul podcastului

www.locustwalk.com

Cel mai nou episod

16 oct. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Biotalk Episode 39: Asia’s 2026 Q3 Report: Global Trends in Biopharma Transactions 16.10.2026

No megadeals, no retreat: China’s average deal fell to $1.7B, but it still holds 58% of global licensing value. In the Asia-focused Episode 39, Geoff Meyerson , CEO of Locust Walk , reviews 2026 Q3 trends across China, Japan, and Korea. Last quarter’s question was whether China’s record deal sizes would hold. They didn’t, but volume did, and that matters more. China: $25B in licensing across 15 de...

Biotalk Episode 38: 2026 Q3 Report: Global Trends in Biopharma Transactions 15.10.2026

M&A has already topped all of 2025, and China still holds 58% of global licensing value. In Episode 38 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2026 Q3 Report: Global Trends in Biopharma Transactions . Licensing: $48B across 41 deals. Value fell 33% from Q2 on just a 5% drop in volume: the story was deal size, as Q2’s megadeals rolled off. Upfronts rebounded to 10% of deal...

Biotalk Episode 37: Asia’s 2026 Q2 Report: Global Trends in Biopharma Transactions 16.07.2026

During the Asia-focused Episode 37 of Biotalk, Geoff Meyerson , CEO of Locust Walk , reviews key trends from the 2026 Q2 Report: Global Trends in Biopharma Transactions , across China, Japan, and Korea. China: Drove ~60% of first-half global licensing value, with the average deal nearing $3B and anchored by the $15B+ Bristol Myers Squibb–Hengrui collaboration. Venture financing posted a second str...

Biotalk Episode 36: 2026 Q2 Report: Global Trends in Biopharma Transactions 16.07.2026

During Episode 36 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2026 Q2 Report: Global Trends in Biopharma Transactions , covering capital markets, strategic deals, and regional trends.  Market Overview: 2026 Q2 confirmed that 2025’s momentum was durable: strategic activity stayed exceptionally strong, public markets kept reopening, and Europe’s venture market rebounded sharply. Ch...

Biotalk Episode 35: Asia’s 2026 Q1 Report: Global Trends in Biopharma Transactions 16.04.2026

During the Asia-focused Episode 35 of Biotalk, Geoff Meyerson , CEO of  Locust Walk , reviews key 2026 Q1 trends across China, Japan, and Korea.  China: Dominated global licensing with 66% of deal value -up from 48% in full-year 2025 -anchored by CSPC–AstraZeneca ($18.5B) and Innovent–Lilly ($8.5B). Venture financing surged to a three-year high of $1.2B across 17 deals, led by Corxel Pharmaceutica...

Biotalk Episode 34: 2026 Q1 Report: Global Trends in Biopharma Transactions 16.04.2026

During Episode 34 of Biotalk,  Geoff Meyerson , CEO of  Locust Walk , unpacks our  2026 Q1 Report: Global Trends in Biopharma Transactions , covering capital markets, strategic deals, and regional trends.   Market Overview: Q1 2026 was defined by continuity rather than reversal. Licensing tied a three-year high, M&A recorded its strongest first quarter ever, and U.S. capital markets reopened m...

Biotalk Episode 33: Asia’s 2025 Year-In-Review Report: Global Trends in Biopharma Transactions 21.01.2026

During the Asia-focused Episode 33 of Biotalk,  Geoff Meyerson , CEO of  Locust Walk , reviews key 2025 Year-In-Review trends across China, Japan, and Korea. China: Led global licensing (~48% share) with larger average deal sizes than the U.S. Public markets outperformed and Q4 IPO activity rebounded. Venture financing held steady, with out-licensing cemented as the dominant business model alongsi...

Biotalk Episode 32: 2025 Year-In-Review Report: Global Trends in Biopharma Transactions 21.01.2026

During Episode 32 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2025 Year-In-Review Report: Global Trends in Biopharma Transactions , covering capital markets, strategic deals, and regional trends.  Market Overview: 2025 marked a clear recovery year for biopharma. Licensing reached record levels, global M&A nearly doubled in value, and capital markets strengthened in the second...

Episode 31: Asia’s 2025 Q3 Report: Global Trends in Biopharma Transactions 20.10.2025

During Episode 31 of Biotalk,  Geoff Meyerson , CEO of  Locust Walk , explores Asia-Pacific biotech momentum across China, Japan, and Korea, as featured in our  2025 Q3 Report: Global Trends in Biopharma Transactions Report . China: Led globally in licensing ($34.2B, 48% share), with venture financing up nearly 4x. Investor confidence rose alongside strong public market gains and creative deal str...

Biotalk Episode 30: 2025 Q3 Report: Global Trends in Biopharma Transactions 20.10.2025

During Episode 30 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2025 Q3 Report: Global Trends in Biopharma Transactions Report , covering capital markets, strategic deals, and regional trends.  Market Overview: Q3 signaled a cautious biotech recovery. Valuations rebounded, the XBI topped 100 for the first time since 2022, and the number of companies trading below cash hit multi-yea...

Episode 29: Asia’s 2025 Q2 Report: Global Trends in Biopharma Transactions 23.07.2025

During the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in Japan, China, Korea, Australia, and the broader Asia-Pacific region, as featured in our 2025 Q2 Report: Global Trends in Biopharma Transactions Report . Japan’s biotech stocks outperformed broader indices, boosted by regulatory reforms and Shionogi’s $1.1B acquisi...

Biotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma Transactions 23.07.2025

During Episode 28 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2025 Q2 Report: Global Trends in Biopharma Transactions Report , covering capital markets, strategic deals, and regional trends.  Market Overview: Biotech remained under pressure in Q2, with valuations still below historical norms. Ongoing macro headwinds—tariffs, high rates, and FDA turnover—kept investor sentiment ca...

Episode 27: Inside the Biopharma Market: 2025 Outlook & Emerging Trends 07.05.2025

During Episode 27 of Biotalk, Geoff Meyerson , CEO of Locust Walk , steps back to examine the macro forces shaping the biopharma landscape. After holding a bearish outlook since 2021, Geoff explains why he’s finally shifting his stance and what could signal a true turnaround for biotech. He unpacks the “big three” market headwinds—regulatory hurdles from the IRA, FTC deal scrutiny, and high intere...

Episode 26: Asia’s 2025 Q1 Report: Global Trends in Biopharma Transactions 16.04.2025

During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson , CEO of  Locust Walk , shares fresh insights from Japan, China, and Korea, as featured in our  2025 Q1 Report: Global Trends in Biopharma Transactions Report .  Japan saw modest market recovery, a $3.3B buyout of Mitsubishi Tanabe, and lighter licensing activity. Early-stage financings picked up as investors re-engaged. China shifted f...

Biotalk Episode 25: 2025 Q1 Report: Global Trends in Biopharma Transactions 16.04.2025

During Episode 25 of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2025 Q1 Report: Global Trends in Biopharma Transactions Report , covering capital markets, strategic deals, and regional trends. Market Overview: The XBI fell 14% YoY, underperforming the NBI. Biotech weakness stemmed from tariff fears, FDA turnover, and HHS layoffs—pressuring small caps. Capital Markets: Capital raise...

Biotalk Episode 24: Asia's 2024 Year-In-Review 28.01.2025

During this episode of Biotalk, Geoff Meyerson , CEO of Locust Walk , explores the evolving biotech landscapes in Japan and China, highlighting key trends and developments shaping the region as featured in our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report . Geoff leverages extensive conversations with strategics and investors worldwide to provide insights into global b...

Biotalk Episode 23: 2024 Year-In-Review Report: Global Trends in Biopharma Transactions 21.01.2025

During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the insights from the comprehensive report and offers a forward-looking perspective on what 2025 may bring for the biotech industry. Key topics include: Capital Markets Performance: The XBI ended flat, down 0.2%, underperformin...

Biotalk Episode 22: A Conversation with Sudhir Agrawal of ARNAY Sciences 10.12.2024

On this episode of Biotalk, Geoff Meyerson, CEO and Co-founder of Locust Walk, speaks with Sudhir Agrawal, Founder and President of ARNAY Sciences and a pioneer in RNA therapeutics. Sudhir’s extensive career spans over three decades, during which he has made groundbreaking contributions to the field, including developing gapmer antisense technology, immune modulation approaches, and, in recent yea...

Biotalk Episode 21: Analyzing the 2024 U.S. Election's Impact on Biotech 24.11.2024

In this episode of Biotalk, Geoff Meyerson , CEO of Locust Walk , is joined by Andy Meyerson , Managing Director, and Daniel Brog , Senior Vice President, for an insightful discussion on the implications of the 2024 U.S. election results for the biotech industry.   The conversation delves into: What Trump's victory could mean for the biotech sector. The potential impact on the HHS and FDA under RF...

Biotalk Episode 20: A Conversation with David Harel of CytoReason 18.11.2024

On this episode of BioTalk, Geoff Meyerson , CEO of Locust Walk , sits down with David Harel , CEO and Co-founder of CytoReason . CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market. David shares his journey from private equity to co-founding CytoReason—...

Biotalk Episode 19: 2024 Q3 Report: Global Trends in Biopharma Transactions 18.10.2024

During this episode of Biotalk, Geoff Meyerson , CEO of Locust Walk , unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report . Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.   In this episode, Geoff provides valuable i...

Biotalk Episode 18: A Conversation with Lindsay Rosenwald of Fortress Biotech 16.08.2024

On this episode of Biotalk, Locust Walk’s  Andy Meyerson  welcomes  Dr. Lindsay Rosenwald , Chairman, President and Chief Executive Officer of  Fortress Biotech , a company focused on licensing and developing high-potential marketed and development-stage drugs. Lindsay shares his journey from physician to biotech entrepreneur and outlines Fortress Biotech’s strategy of licensing high-potential mar...

Biotalk Episode 16: A Conversation with Stephen Sands of Lazard 15.05.2024

On this episode of Biotalk, Locust Walk’s  Geoff Meyerson  welcomes  Stephen Sands , former Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group, and currently Senior Advisor at  Lazard , a renowned name in global financial services. Together, they explore Stephen’s journey into life sciences finance, his transition into financial and management roles within healthcare,...

Biotalk Episode 15: 2024 Q1 Report: Global Trends in Biopharma Transactions 16.04.2024

During this episode of Biotalk,  Geoff Meyerson , CEO of  Locust Walk , unpacks our  2024 Q1 Report: Global Trends in Biopharma Transactions Report . Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.   In this episode, Geoff provides valuabl...

Biotalk Episode 13: 2023 Year-In-Review Report: Global Trends in Biopharma Transactions​ 24.01.2024

In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: XBI performance and IPO volume Private biotech markets: Financing deal value and volume remained flat Strategic transaction activity: Q4 marked a surge in multi-billion-dollar acquisitions Market outlook and advice for the year ahead We invite you to listen to our podcast...

Ascultă podcastul Biotalk în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice